Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma
Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, F-67000 Strasbourg, France
Université de Strasbourg, F-67000 Strasbourg, France
Institut Hospitalo-Universitaire, Pôle Hépato-digestif, Nouvel Hôpital Civil, F-67000 Strasbourg, France
Liver Tumor Translational Research Program, Harold C. Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Authors to whom correspondence should be addressed.
Received: 13 May 2019 / Accepted: 14 May 2019 / Published: 15 May 2019
PDF [168 KB, uploaded 15 May 2019]
Note: In lieu of an abstract, this is an excerpt from the first page.
Chronic hepatitis C virus (HCV) infection is a major cause of liver disease and hepatocellular carcinoma (HCC)—the second leading, and rising, cause of death due to cancer world-wide [...]
This is an open access article distributed under the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Baumert, T.F.; Hoshida, Y. Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma. Viruses 2019, 11, 441.
Baumert TF, Hoshida Y. Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma. Viruses. 2019; 11(5):441.
Baumert, Thomas F.; Hoshida, Yujin. 2019. "Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma." Viruses 11, no. 5: 441.
Show more citation formats
Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
[Return to top]
For more information on the journal statistics, click here
Multiple requests from the same IP address are counted as one view.